<DOC>
	<DOCNO>NCT00321854</DOCNO>
	<brief_summary>This double blind , placebo-controlled clinical trial 15 month duration design examine early Mirapex ( pramipexole ) treatment vs. delay Mirapex ( pramipexole ) treatment patient new onset Parkinsons disease</brief_summary>
	<brief_title>Study ( Mirapex ) Pramipexole Early Treatment Parkinsons Disease ( PD )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Ability provide write informed consent accordance Good Clinical Practice ( GCP ) local legislation ; Male female patient idiopathic Parkinson Disease ( PD ) confirm least three follow sign : rest tremor , bradykinesia , rigidity , asymmetry ( must bradykinesia ) ; Parkinsons disease newly diagnose within past 2 year ; Patients idiopathic PD characterize Stage III Modified Hoehn Yahr Scale require PD medication likely need PD medication least 6 month opinion investigator ; Age 30 75 year screen ( Visit 1 ) ; Women childbearing potential must negative serum BetaHumanChorionGonadotropin ( BetaHCG ) pregnancy test Screening ( Baseline ) visit unless surgically sterile postmenopausal ( last menstruation 12 month prior sign Informed Consent ) . Women childbearing potential must use medically accept contraceptive method . Acceptable method birth control limit : IntraUterine Device ( IUD ) , oral , implantable , injectable contraceptive , estrogen patch , double barrier method ( spermicide + diaphragm ) ; Patients willing able comply schedule visit , treatment plan , laboratory test , study procedure . Previous history allergic response complication pramipexole ( PPX ) excipients ; Atypical PD syndrome due either drug ( e.g. , metoclopramide , flunarizine ) metabolic disorder ( e.g. , Wilsons Disease ) , encephalitis , degenerative disease ( e.g. , progressive supranuclear palsy ) ; The patient currently Ldopa , dopamine agonist PD medication baseline ; The patient Ldopa , dopamine agonist PD medication great 14 consecutive day prior baseline ; If Ldopa , dopamine agonist PD medication prior baseline , patient stop treatment le 30 day prior baseline ; The patient clinically significant abnormal laboratory value , and/or medical psychiatric illness see Parkinsons disease ; The patient clinically significant deviation normal physical examination see Parkinsons disease ; The patient disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) ; History stereotactic brain surgery ; Surgery within 6 month randomization , opinion investigator , would negatively impact patient participation study ; History active epilepsy ( i.e. , occurrence seizure ) within past year ; Symptomatic orthostatic hypotension prior randomization ; Malignant melanoma history previously treat malignant melanoma ; Patients receive follow drug ( time period calculate randomization ) : Amantadine ; Electroconvulsive therapy 180 day precede screen visit ( Visit 1 ) ; Patients currently pregnant plan pregnancy study , lactate ; Participation investigational drug study use investigational drug within previous 30 day prior randomization ; History psychosis ; A diagnosis dementia</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>